Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Mohamed L. Sorror, Michael B. Maris, Rainer Storb et al. · Blood · 2005 · 2.9K citations · Full text

Medicine, Hematology, Risk Assessment +11

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi, Larry D. Anderson, Nina Shah et al. · New England Journal of Medicine · 2021 · 2.4K citations · Full text

Medicine, Hematology, Oncology +17

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Antonio Palumbo, Hervé Avet‐Loiseau, Stefania Oliva et al. · Journal of Clinical Oncology · 2015 · 2.2K citations · Full text

Medicine, Hematology, Oncology +16

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.7K citations

Medicine, Hematology, Oncology +17

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17